This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana
by Zacks Equity Research
Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.
3 Top-Ranked Medical Stocks Lapping the S&P 500
by Derek Lewis
All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are anticipated to have enhanced consumer engagement across all CVS Health businesses in Q3.
McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.
What's in the Cards for Illumina (ILMN) in Q3 Earnings?
by Zacks Equity Research
The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.
Zacks.com featured highlights include Boise Cascade, RCI Hospitality Holdings, Iron Mountain, McKesson and National Fuel Gas
by Zacks Equity Research
Boise Cascade, RCI Hospitality Holdings, Iron Mountain, McKesson and National Fuel Gas are part of Zacks Screen of the week article.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q4 Earnings
by Zacks Equity Research
Hologic's (HOLX) Molecular Diagnostics sales are likely to have been affected by the significant drop in demand for COVID-19 testing.
5 Solid Dividend Growth Stocks for Q4
by Sweta Killa
Boise Cascade (BCC), RCI Hospitality (RICK), Iron Mountain (IRM), McKesson (MCK) and National Fuel Gas (NFG) seem compelling picks for Q4 amid volatility.
Should Investors Consider These 3 Warren Buffett Purchases?
by Derek Lewis
Many people turn to the Oracle of Omaha when looking for stocks to add. After all, it's easy to understand why after seeing his track record.
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.
Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.